Clinical trials: Biliary Cancers
Biliary Tract Neoplasms
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
- Trial name
- TOPAZ-1 (NCT03875235)
- Testing
- Durvalumab
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 810 people
- Sponsor
- AstraZeneca
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00363584
- Testing
- capecitabine, clinical observation, adjuvant therapy
- Where
- 46 sites in United Kingdom
- Volunteers
- 360 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Biliary Tract Cancer
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
To decide maximum tolerated dose and/or recommended dose of Gemcitabine or S-1 adjuvant therapy after hemihepatectomy
- Trial name
- NCT01291615
- Testing
- Gemcitabine, S-1
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Esophageal Cancer, Gastric Cancer
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
This phase I trial is to investigate the safety and the possible side effects of bi-specific antibody armed T-cell therapy when given together with low-dose IL-2 in treating patients with Her2-positive neoplasms of digestive…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT02662348
- Testing
- Recombinant Human Interleukin-2, HER2Bi-Armed T Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Yi Miao
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Cholangiocarcinoma, Hilar Lymphadenopathy
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
The optimal approach to the drainage of malignant obstruction at the biliary hilum remains uncertain. This is a randomized comparative effectiveness study of percutaneous transhepatic biliary drainage (PTBD) vs.
- Conditions
- Cholangiocarcinoma, Hilar Lymphadenopathy, Biliary Stricture
- Trial name
- INTERCPT (NCT03172832)
- Testing
- PTBD, ERC
- Where
- 25 sites in United States
- Volunteers
- 13 people
- Sponsor
- Medical University of South Carolina
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Gallbladder Neoplasms
Chinese Research Group of Gallbladder Cancer
The Chinese Research Group of Gallbladder Cancer (CRGGC) is a retrospective multicenter registry cohort, collecting electronic medical records of patients diagnosed with gallbladder cancer from hospitals in collaboration.
- Trial name
- CRGGC (NCT04140552)
- Where
- 55 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Biliary Tract Cancer
A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis
To evaluate the efficacy and the safety of preoperative chemotherapy with Gemcitabine/ Cisplatin /S-1 for biliary tract cancers with lymph node metastasis by FDG-PET.
- Trial name
- NCT01821248
- Testing
- Gemcitabine, Cisplatin, S-1
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Biliary Disease, Pancreatitis
Los Angeles Prospective GI Biliary and EUS Series
Endoscopic retrograde cholangiopancreatography and endoscopic ultrasound are increasingly being used to manage complex disease of the bile duct, pancreas and cancer.
- Conditions
- Biliary Disease, Pancreatitis, Gastrointestinal Neoplasms
- Trial name
- NCT02196935
- Testing
- clinical course
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- University of Southern California
Biliary Tract Carcinoma, Gallbladder Carcinoma
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
This is a phase II study (the second stage of testing a new drug or new drug combinations) to see how useful two different schedules of study drug selumetinib with cisplatin and gemcitabine are compared to cisplatin and…
- Trial name
- NCT02151084
- Testing
- Selumetinib, Cisplatin, Gemcitabine
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- University Health Network, Toronto
Biliary Tract Cancer
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
Advanced biliary tract cancer has a poor prognosis and limited efficacy with current regimens. This multicenter single-arm phase Ib/II trial explores the efficacy and safety of HAI-GP chemotherapy combined with intraoperative…
- Trial name
- NCT07636798
- Testing
- HAIC Combined Regimen Treatment Group
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Metastatic Biliary Tract Cancer
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
- Trial name
- NCT06548412
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Gall Bladder Carcinoma
Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality
Incidental gallbladder carcinoma :Incidence and clinical significance in specimens from routine cholecystectomies in sohag locality
- Trial name
- NCT07885800
- Testing
- histopathology of gall bladder
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Advanced Biliary Tract Cancer, Neuroendocrine Tumors
Combination Immunotherapy in Rare Cancers Under InvesTigation
The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1.
- Conditions
- Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
- Trial name
- MOST-CIRCUIT (NCT04969887)
- Testing
- Ipilimumab, Nivolumab
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 240 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Cholangiocarcinoma
Comparison of Biliary Forceps Biopsy and Brush Cytology
Cholangiocarcinomas (CCCs) are malignant tumors arising from the biliary epithelium. CCCs are characterised by a high mortality and the only curable therapy is complete tumor resection, if feasible, or in some cases liver…
- Trial name
- NCT01145248
- Testing
- double-balloon enteroscopy forceps biopsy, Transpapillary brush cytology
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- University of Ulm
Pancreatic Cancer, Common Bile Duct Diseases
A Prospective Clinical Study Using an Artery-first Intermediate Approach in Robot-assisted Pancreaticoduodenectomy
Pancreaticoduodenectomy, as a standard surgical procedure for malignant tumors of the head of the pancreas, ampulla and distal common bile duct, has brought the hope of clinical cure for these diseases.In the whole surgical…
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05660915
- Testing
- Intermediate approach, Standard approach
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of University of South China
Gallbladder Cancer, Cholangiocarcinoma
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
The goal of this clinical trial is to evaluate the efficacy and safety of combining Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab in adults aged 18-75 years with advanced unresectable biliary tract malignancies…
- Trial name
- GALENT-BT (NCT06963060)
- Testing
- Gemcitabine nab-PaclitaxelLenvatinibTislelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Wei Gong
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Biliary Tract Cancer
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
This research aims to study the effect of postoperative adjuvant therapy with a MiniPDX drug sensitivity test for biliary tract cancer.
- Trial name
- NCT07156058
- Testing
- MiniPDX group, Capecitabine
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.